Watch SANA. Know when insiders buy.
One email the day a filing lands. Free.
SANA
Sana Biotechnology, Inc.
2.91
−0.03 −1.19%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $871.1MP/E —DIV YIELD —FCF YIELD -15.50%REV TTM —NET INCOME −$211.8MNET CASH —52W 2.68 – 5.92SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$65.4M | −$63.6M | — | -0.22 | −$32.8M | $1.6M | −$34.4M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$48.6M | −$47.2M | — | -0.17 | −$37.4M | $288K | −$37.7M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$61.2M | −$58.8M | — | -0.21 | −$32.6M | $873K | −$33.5M | Mar 3 |
| Q3 2025 · Sep 30 | — | — | — | −$43.5M | −$42.2M | — | -0.16 | −$29.4M | $41K | −$29.5M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$95M | −$93.8M | — | -0.39 | −$33.1M | −$112K | −$33M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$50.6M | −$49.4M | — | -0.21 | −$48.7M | $136K | −$48.8M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$50.9M | −$49.1M | — | -0.21 | −$47.2M | $436K | −$47.6M | Mar 3 |
| Q3 2024 · Sep 30 | — | — | — | −$61.8M | −$59.9M | −6189.8% | -0.25 | −$51.8M | $4.1M | −$55.9M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$49.4M | −$50.3M | — | -0.21 | −$58.5M | $13.1M | −$71.6M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$110.7M | −$107.5M | — | -0.49 | −$65.6M | $15.8M | −$81.5M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$90.6M | −$88.1M | — | -0.45 | −$52M | $14M | −$66M | Mar 3 |
| Q3 2023 · Sep 30 | — | — | — | −$2.2M | $984K | — | 0.00 | −$63.5M | $2.2M | −$65.8M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$250.3M | −$244.2M | — | -0.96 | −$143.8M | $938K | −$144.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$272.7M | −$266.8M | — | -1.16 | −$223.2M | $33.4M | −$256.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$293.1M | −$283.3M | — | -1.46 | −$253.6M | $20M | −$273.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$272.6M | −$269.5M | — | -1.43 | −$290.1M | $20.9M | −$310.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$356.9M | −$355.9M | — | -2.14 | −$251.1M | $29.9M | −$280.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$286.1M | −$285.3M | — | -21.92 | −$138M | $23.9M | −$161.9M | — | — |
Every number comes from Sana Biotechnology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.